Remus Pharmaceuticals Limited
NSE: REMUS
Remus Pharmaceuticals Limited is an Indian listed company, traded under NSE: REMUS (ISIN INE0O5T01011).
It has a market capitalisation of ₹1,160 crore, a last close of ₹984.50 on 2026-10-19, a one-year return of 48.0%.
Valuation: a price-to-earnings ratio of 31.35x, a price-to-book ratio of 3.30x, a dividend yield of 0.0%.
Profitability: return on equity of 12.2%, return on capital employed of 16.4%, an operating margin of 6.6%.
Balance sheet and ownership: debt-to-equity of 0.07x, promoter holding of 71.0%.
| Metric | Value |
|---|---|
| Market capitalisation | 1,160 |
| Last close | ₹984.50 |
| P/E (TTM) | 31.35x |
| P/B | 3.30x |
| Dividend yield | 0.0% |
| ROE (FY) | 12.2% |
| ROCE (FY) | 16.4% |
| Operating margin (TTM) | 6.6% |
| Debt / equity | 0.07x |
| Promoter holding | 71.0% |
| 1-year return | 48.0% |
Loading the live page with the price chart, financial history, shareholding and recent filings. Data is end-of-day and rebuilt nightly; nothing here is investment advice. Financial statements · What each metric means